Drugmakers Pay Out On Claw-Back Tax

BMI View: Industry anger against the Romanian claw-back tax is likely to remain but in the short-term it looks like the legal actions to fight it have failed. The unpredictability of this tax, as it is based on National Health Insurance House (CNAS) overspend against their own underfunded budgets, makes the levy particularly burdensome for drugmakers operating in the country.

To read the full article, please choose one of the following options: